Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance
Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance
复制标题
DOI：
10.1016/j.ijantimicag.2015.08.010
复制
发表时间：
2015-12-01
影响因子：
10.8
通讯作者：
Mitov, Ivan
中科院分区：
文献类型：
--
作者：
Boyanova, Lyudmila;Evstatiev, Ivailo;Mitov, Ivan
只有少数研究评价了幽门螺杆菌对利奈唑胺的敏感性。本研究的目的是评估利奈唑胺在H. pylori，包括具有双重/多重耐药性的菌株。53 H.用Etest和折点敏感性试验方法对pylon菌株进行评价。幽门螺杆菌耐药率如下：阿莫西林，1.9%;甲硝唑，37.7%;克拉霉素，17.0%;四环素，1.9%;左氧氟沙星，24.5%;利奈唑胺（>4 mg/L），39.6%。利奈唑胺MIC 50值是克拉霉素的31.2倍，是左氧氟沙星的10.5倍;然而，11株双重/多重耐药菌株中有4株对利奈唑胺敏感。与前两篇报道相比，恶唑烷酮类药物的MIC范围更大（0.125-64 mg/L）。甲硝唑耐药菌株和对至少一种抗生素耐药的菌株中的利奈唑胺耐药率是其余菌株的2.2倍。简言之，利奈唑胺对H.与克拉霉素和左氧氟沙星相比，利奈唑胺耐药与甲硝唑耐药以及至少一种抗生素耐药有关。然而，利奈唑胺对某些双重/多药耐药菌株的活性可能使该药物适用于治疗某些相关的H。菌株体外敏感性试验后的pylon感染。需要临床试验来证实这一建议。(C)2015年Elsevier B. V.和国际化疗学会。All rights reserved.
Only a few studies have evaluated Helicobacter pylon susceptibility to linezolid. The aim of the present study was to assess linezolid susceptibility in H. pylori, including strains with double/multidrug resistance. The susceptibility of 53 H. pylon strains was evaluated by Etest and a breakpoint susceptibility testing method. Helicobacter pylon resistance rates were as follows: amoxicillin, 1.9%; metronidazole, 37.7%; clarithromycin, 17.0%; tetracycline, 1.9%; levofloxacin, 24.5%; and linezolid (>4 mg/L), 39.6%. The linezolid MIC50 value was 31.2-fold higher than that of clarithromycin and 10.5-fold higher than that of levofloxacin; however, 4 of 11 strains with double/multidrug resistance were linezolid-susceptible. The MIC range of the oxazolidinone agent was larger (0.125-64 mg/L) compared with those in the previous two reports. The linezolid resistance rate was 2.2-fold higher in metronidazole-resistant strains and in strains resistant to at least one antibiotic compared with the remaining strains. Briefly, linezolid was less active against H. pylon compared with clarithromycin and levofloxacin, and linezolid resistance was linked to resistance to metronidazole as well as to resistance to at least one antibiotic. However, linezolid activity against some strains with double/multidrug resistance may render the agent appropriate to treat some associated H. pylon infections following in vitro susceptibility testing of the strains. Clinical trials are required to confirm this suggestion. (C) 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.